Spinal cord injury, frontotemporal dementia, traumatic brain injury and ALS are just some examples of neurodegenerative diseases caused by trauma, infection, genetic deformities or ageing. These conditions seem diverse but share a common degenerative pathway at cellular level: inflammation that causes further damage, myelinization that restricts signal transmission, and hampered restoration mechanisms.

 

Neuro-Cells® focusses on those underlying cellular processes that neurodegenerative diseases have in common.

​

Our technology calls on the self-healing capacity of non-manipulated stem cells, that the body itself is unable to leverage for neurodegenerative conditions due to the blood brain barrier.

​

Neuro-Cells® includes a mixture of stem cells types that "know" how to address these processes where they fail, and in close coordination with each other, restore the balance between them. 

​

The therapy adjusts itself to the microenvironment and is able to combat inflammation, loss of myeline and hampered restoration at the same time, at an interplay that is appropriate for the disease type and stage of its development.

 

The goal is to reduce damage and degeneration and to improve regeneration potential.

​

Neuro-Cells®:

• Is derived from the bone marrow of the patient itself

• Does not include any genetic engineering

• Follows an 8-hour patented production process

• Is reinjected into the site of injury

• Leverages the cell-mixtures natural ability to restore balance and interplay at cellular level

​

With two European Orphan Designations, Neuroplast is following a fast-track development path to market authorization, with ten-year market exclusivity, for Traumatic Spinal Cord Injury and Frontotemporal Dementia. Safety has already been proven for Traumatic Spinal Cord Injury, and its efficacy is currently being studied in a combined phase II-III clinical trial. Next to that, there is further evidence suggesting application for Traumatic Brain Injury, ALS and Parkinson's disease.